Revance Therapeutics Inc. (RVNC) Surged To A New High On Study Results

Revance Therapeutics Inc. (RVNC) announced Tuesday morning that its two Phase 3 trials of RT002 injection met their primary and all secondary endpoints in patients with Glabellar lines.

from RTT - Before the Bell http://ift.tt/2jYoCt8
via IFTTT